Quantitative analysis for PDS Biotechnology Corporation (PDSB) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Strong Sell (27.0) (grade F). 24 signals analyzed (21 differentiated alt-data).
PDSB stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $1.14 | $0.96 | $0.96 |
| 2026-05-11 | $1.35 | $1.21 | $1.30 |
| 2026-05-21 | $1.18 | $1.02 | $1.16 |
| 2026-06-03 | $1.18 | $1.07 | $1.08 |
| 2026-06-15 | $1.14 | $1.01 | $1.02 |
| 2026-06-26 | $0.94 | $0.86 | $0.89 |
| 2026-07-09 | $0.84 | $0.74 | $0.79 |
| 2026-07-21 | $0.77 | $0.72 | $0.76 |
| 2026-07-31 | $0.70 | $0.67 | $0.69 |
| 2026-08-12 | $0.27 | $0.23 | $0.24 |
| 2026-08-24 | $0.22 | $0.21 | $0.22 |
| 2026-09-03 | $0.23 | $0.21 | $0.22 |
How PDS Biotechnology Corporation stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| BGM | BGM Group Ltd. | $59M | — |
| CHRN | Ekso Bionics Holdings, Inc. Common Stock | $56M | — |
| ACRV | Acrivon Therapeutics, Inc. Common Stock | $56M | — |
| FLNA | Filana Therapeutics, Inc. | $60M | — |
View all Health Care stocks by valuation and signals →
PDS Biotechnology Corporation (PDSB) scores Strong Sell (27.0), and the composite conceals a 73-point disagreement between its dimensions. It is strongest on analyst consensus at 74, and weakest on technicals at 33 and competitive moat at 1. A stock can carry analyst consensus that high while competitive moat sits at 1; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 74 |
| technicals | 33 |
| competitive moat | 1 |
StoQuant analyzes 24 signals (21 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on PDS Biotechnology Corporation (PDSB): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/PDSB"><img src="https://stoquant.com/badge/PDSB.svg" alt="PDS Biotechnology Corporation (PDSB) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.